Electronic NDA Rule Should Be Phased In Over 3 Years, Small Firms Say
This article was originally published in The Tan Sheet
Executive Summary
Small pharmaceutical companies favor FDA's proposal to move from paper to electronic filing of regulatory submissions but want a three-year grace period following the agency's issuance of a final rule